

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

INSIDE INFORMATION

(1) FURTHER DELAY IN PUBLICATION OF 2024 ANNUAL RESULTS AND DESPATCH OF ANNUAL REPORT 2024;

AND

(2) CONTINUED SUSPENSION OF TRADING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Sinopharm Tech Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 30 September 2024 (the “**Announcement**”) in relation to, among others, (i) delay in publication of 2024 Annual Results and despatch of Annual Report 2024; and (ii) suspension of trading. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

FURTHER DELAY IN PUBLICATION OF 2024 ANNUAL RESULTS AND DESPATCH OF ANNUAL REPORT 2024

The publication of the Company’s annual results announcement for the year ended 30 June 2024 (the “**2024 Annual Results**”) and the Board meeting in respect of reviewing and approving,

among other matters, the 2024 Annual Results are expected to be further postponed to on or before 31 December 2024 as the Company's auditor, SFAI (HK) CPA Limited, needs more time to complete its audit process. Accordingly, the publication and despatch of the 2024 Annual Report as required under Rules 18.48A and 18.03 of the GEM Listing Rules will also be postponed. The Company will continue to use its best endeavours to facilitate the completion of the audit process and strives to publish the 2024 Annual Results and publish and despatch the Annual Report 2024 by 31 December 2024.

As at the date of this announcement, the reasons for further delay in publication of 2024 Annual Results are that the key outstanding audit documentation for the completion of the audit procedures covers three aspects, namely (i) review of the results of valuation on credit impairment assessments on the Group's receivables; (ii) review of the results of valuation on the financial assets at fair value through profit or loss of the Group; and (iii) final internal review of the audit work conducted.

The Company will publish further announcement(s) to inform the shareholders and potential investors of the Company of any material developments in connection with the 2024 Annual Results and the Annual Report 2024 as and when appropriate.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, 2 October 2024 pending the publication of the 2024 Annual Results.

The shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
HO Kam Kin
Executive Director

Hong Kong, 26 November 2024

As at the date of this announcement, the Board comprises Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at <https://www.hkexnews.hk> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.